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Abstract
Background: Clinical significance of microscopic peritoneal carcinomatosis remained unclear. The aim of this study was to
evaluate the prognostic value of microscopic peritoneal carcinomatosis in gastric cancer.
Methods: From 1996 to 2007, 4426 patients underwent gastrectomy for gastric cancer at Fudan University Shanghai Cancer
Center. The clinical and pathological data were reviewed to identify patients with microscopic peritoneal carcinomatosis
(group 1). The clinicopathological features and prognosis were examined. Additionally, 242 stage-matched gastric cancer
patients without microscopic peritoneal carcinomatosis (group 2) and 118 with macroscopic peritoneal carcinomatosis
(group 3) were selected as control groups.
Results: Microscopic peritoneal carcinomatosis was found in 121 patients. There were 85 males and 36 females (2.36:1).
There was a higher incidence rate of large size tumor ($5 cm) (P=0.045), Borrmann IV (P=0.000), and serosal invasion
(P=0.000) in gastric cancer with microscopic peritoneal carcinomatosis compared with the control group. The 5-year
survival rate of gastric cancer with microscopic peritoneal carcinomatosis was 24%, significantly poorer than that of the
stage-matched control group but better than that of patients with macroscopic peritoneal carcinomatosis. The independent
prognostic factors identified included pathological stage and operative curability.
Conclusions: The presence of microscopic peritoneal carcinomatosis was associated with worse prognosis for gastric
cancer, but curative surgery showed potential to improve prognosis.
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Introduction
Although the incidence of gastric cancer has been substantially
declining for several decades, it remained the fourth most common
cancer and the second most frequent cause of cancer death
worldwide [1,2]. It was very important to predict precisely the risk
of poor prognosis in order to maximize the therapeutic effect and
to minimize the adverse effects in the treatment of cancer patients.
Among the prognostic factors now available for gastric cancer, the
most precise and useful prognostic factor was the UICC TNM
(tumor, lymph node, and metastasis) staging stage. Peritoneal
metastasis was considered to be one of the metastasis, and was one
of the most common types of spread and the causes of death [3].
Peritoneal metastasis of gastric cancer was considered to be
operation contraindication and the most difficult type for
treatment [4]. The peritoneal metastasis was mainly classified
classified as macroscopic peritoneal carcinomatosis (overt perito-
neal dissemination) and positive peritoneal lavage cytology, and
their prognostic value has been extensively investigated in gastric
cancer. However, tumor nodules were occasionally found in the
peritoneal of gastric cancer patients by histopathological exami-
nation. We defined this kind of peritoneal dissemination as
microscopic peritoneal carcinomatosis compared with macroscop-
ic peritoneal carcinomatosis. There was currently no evidence as
to the clinical significance of microscopic peritoneal carcinoma-
tosis in gastric cancer.
The objectives of this study were to investigate the clinical
significance of microscopic peritoneal carcinomatosis and to assess
the impact of microscopic peritoneal carcinomatosis on survival
related to clinicopathological characteristics in patients with
resectable gastric cancer.
Materials and Methods
From January 1996 to December 2007, 4426 patients with
histologically confirmed primary gastric adenocarcinoma under-
went gastrectomy at the Department of Surgery in Fudan
University Shanghai Cancer Center. The electronic records of
these patients were reviewed, and patients with microscopic
peritoneal carcinomatosis were included in this study. Microscopic
peritoneal carcinomatosis was defined as the nodules without any
evidence of lymph node tissue or lymph node architecture, and
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resected peritoneum included greater omentum, lesser omentum,
and transverse mesocolon according to guideline of gastric cancer
therapy.
Additionally, 242 stage-matched gastric cancer patients without
peritoneal dissemination (group 2) and 118 with macroscopic
peritoneal carcinomatosis (group 3) were selected as control. All
patients of group 3 received gastrectomy. Before operations, all
patients were routinely performed upper gastrointestinal barium-
meal, endoscopic examination, abdominal ultrasound, and com-
puted tomographic scan. Staging was performed according to the
American Joint Committee on Cancer (AJCC) TNM Staging
Classification for Carcinoma of the Stomach (7th edition, 2010).
Data were retrieved from patients’ operative and pathological
reports, and follow-up data were obtained by phone, letter, and
the out-patient clinical database. The written informed consent
had been obtained from all the patients, and this study was
approved by the Ethical Committee of Shanghai Cancer Center of
Fudan University. The study was retrospective.
Follow-Up
Postoperative follow-up included physical examination, imaging
examination, and laboratory examination every three months for
the first two years at the outpatient, every six months for the next 3
years, and after 5 years every 12 months for life. Overall survival,
which was used as a measure of prognosis, was defined as time
from operation to death or last follow-up.
Statistical analysis
The clinicopathological comparisons between patients with
microscopic peritoneal carcinomatosis and control groups were
evaluated by Fisher exact test. Five-year survival rates were
calculated by Kaplan-Meier method, and differences between
survival curves were examined with Log-rank test. The accepted
level of significance was P,0.05. Statistical analyses and graphics
were performed with the SPSS 13.0 statistical package (SPSS, Inc.,
Chicago, IL).
Results
Clinicopathological characteristics
There were 85 males and 36 females (2.36:1) with a mean age of
59 years. According to histological type, well-differentiated were
observed in 2 (1.7%) patients, moderately-differentiated in 28
(23.1%) patients, and poorly-differentiated in remaining 91
(75.2%) patients. According to Borrmann type, 9 (7.4%) type I,
1 (0.8%) type II, 100 (82.6%) type III, 11 (9.1%) type IV. Of 121
patients, 37 (30.6%) had tumors located in the upper third, 31
(25.6%) had tumors in the middle third, 45 (37.2%) had tumors in
the lower third of the stomach, and 8 (6.6%) had tumors occupied
two-thirds or more of stomach. Lymph node metastasis was
observed in 101 patients, the total metastasis rate was 83.5%. The
distribution of pathological stage was as follows: 4 (3.3%) patients
belonged to stage IB, 18 (14.9%) IIB, 19 (15.7%) IIIA, 33 (27.3%)
IIIB, 88 (17.6%) IIIA, 47 (38.8%) IIIC.
Clinicopathologic characteristics of patients with microscopic
peritoneal carcinomatosis (group 1) were compared with that of
gastric cancer without microscopic peritoneal carcinomatosis
(group 2) and gastric cancer with macroscopic peritoneal
carcinomatosis (group 3). Results showed that sex, tumor location,
histology type, and surgical properties were similar between group
1 and group 2. There was a higher incidence rate of older patients
($60) (P=0.012), large size tumor ($5 cm) (P=0.045), Borrmann
IV (P=0.000), and serosal invasion (P=0.000) in group 1(Table 1).
There were significant differences of age and tumor location
between group 1 and group 3 (Table 2).
Tumor nodules features
Microscopic peritoneal carcinomatosis was located in the
different location of peritoneal. 83 (68.6%) had microscopic
peritoneal carcinomatosis located in the serosal surface of stomach,
27 (22.3%) had it in greater omentum, 2 (1.7%) had it in lesser
omentum, 4 (3.3%) in transverse mesocolon, and 5 (4.1%) had it
occupied in two or more parts. Single microscopic peritoneal
carcinomatosis was found in 62 patients, two or more microscopic
peritoneal carcinomatoses were found in other patients. The total
number of microscopic peritoneal carcinomatosis was 249 (mean
2.0 and median 1.0 per patient).
Prognosis
The 1-, 3-, 5-yr survival rates of the gastric cancer with
microscopic peritoneal carcinomatosis were 73%, 41%, and 24%,
respectively, the 1-, 3-, 5-yr survival rates of the gastric cancer
without microscopic peritoneal carcinomatosis were 85%, 47%,
Table 1. Comparison of Clinicopathological Features
Between gastric cancer patients with microscopic peritoneal
carcinomatosis (group 1) and gastric cancer without
microscopic peritoneal carcinomatosis (group 2).
Variables Group 1 Group 2 P
Sex (M/F) 85/36 165/77 0.689
Age ($60/,60) 70/51 106/136 0.012
Histology type (P/M/W)* 91/28/2 180/61/1 0.408
Operation curability (yes/no) 102/19 206/36 0.836
Tumor size ($5/,5) 71/50 115/127 0.045
Borrmann type IV (yes/no) 11/110 1/241 0.000
Serosal invasion (yes/no) 114/7 122/120 0.000
Tumor location (C/M/A and two
or more)#
37/31/45/8 80/42/106/14 0.280
*Poorly differentiated/moderately differentiated/well differentiated.
#Corpus/middle/antrum.
doi:10.1371/journal.pone.0037284.t001
Table 2. Comparison of Clinicopathological Features
Between gastric cancer patients with microscopic peritoneal
carcinomatosis (group 1) and gastric cancer with macroscopic
peritoneal carcinomatosis (group 3).
Variables Group 1 Group 3 P
Sex (M/F) 85/36 74/44 0.217
Age ($60/,60) 70/51 49/69 0.012
Histology type (P/M/W)* 91/28/2 97/18/3 0.263
Tumor size ($5/,5) 71/50 69/49 0.975
Borrmann type IV (yes/no) 11/110 19/99 0.102
Serosal invasion (yes/no) 114/7 103/15 0.064
Tumor location (C/M/A and two
or more)#
37/31/45/8 16/35/45/22 0.002
*Poorly differentiated/moderately differentiated/well differentiated.
#Corpus/middle/antrum.
doi:10.1371/journal.pone.0037284.t002
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peritoneal carcinomatosis were 47%, 6%, and 6%. These
differences were statistically significant among three groups
(P=0.000) (Figure 1). The significant prognostic factors of the
gastric cancer with microscopic peritoneal carcinomatosis includ-
ed: the number of tumor nodules, serosal invasion, operative
curability, lymph node metastasis, and pathological stage. The
independent prognostic factors included: pathological stage and
operative curability (Table 3). The 5-year survival rate was 28% in
patients who underwent curative surgery.
Discussion
Gastric cancer was one of the most common malignancies
around the world. Although the prognosis of patients with gastric
cancer has improved as a result the availability of diagnostic
techniques and better therapy strategy, gastric cancer was still the
second leading cause of cancer related deaths [2]. The dismal
prognosis of gastric cancer was due principally to the frequent
metastasis. The most frequent type of metastasis in gastric cancer
was peritoneal carcinomatosis (PC) [5]. In the Japanese Rules of
Gastric Cancer, PC was classified into five categories: P0/Cy0,
P0/Cy1, P1, P2 and P3. P0/Cy0 denoted no macroscopic disease
and negative peritoneal wash cytology; P0/Cy1 meant no
macroscopic PC but positive peritoneal wash cytology; P1 denoted
PC in the upper abdomen above the transverse colon; P2 meant
several countable PC in the peritoneal cavity; and P3 meant
numerous PC in the peritoneal cavity. However, we found that
some tumor nodules were occasionally found in the peritoneal of
gastric cancer patients by histopathological examination. This kind
of peritoneal carcinomatosis entitled as microscopic peritoneal
carcinomatosis was not included into the gastric cancer staging
system. The prognostic significance of microscopic peritoneal
carcinomatosis in gastric cancer was still unclear. There have been
no prior reports in the literature investigating this type of
peritoneal dissemination, and therefore the incidence of micro-
scopic peritoneal carcinomatosis remained unknown. In this study,
121 patients were classified as having microscopic peritoneal
carcinomatosis based on the histologic examination, the incidence
was 2.7%, which was lower than that of the macroscopic
peritoneal carcinomatosis or positive peritoneal lavage cytology
[6,7].
In this study, we found that there was a higher incidence of large
size tumor, Borrmann IV, and serosal invasion in gastric cancer
patients with microscopic peritoneal carcinomatosis than that of
patients without microscopic peritoneal carcinomatosis. In one of
the earlier study, Kostic ´ et al. [8] showed that a tumor diameter
.5 cm, tumor invasion of serosa, histopathological stage of the
disease III and IV, and macroscopically visible metastases were the
most important risk factors for detection of free cancer cells in
patients surgically treated for gastric adenocarcinoma. The exact
mechanism that was contributing to microscopic peritoneal
carcinomatosis was still not clear. Yonemura [9] suggested that
peritoneal dissemination was associated with lymphatic orifices of
peritoneal surfaces. The orifices were referred to as the lymphatic
stomata, and connected with the subperitoneal lymphatic channel
and milky spots. Milky spots were the minute organelles, which
contained lymphatic vessels, lymphocytes, and peritoneal macro-
phages. Intraperitoneal free cancer cells specifically deposited in
the lymphatic stomata, and proliferated in the submesothelial
lymphatic space. Additionally, they also found that milky spots
distributed mainly on the greater omentum and pelvic peritone-
um. According to this theory, we hypothesized that peritoneal
cancer nodules should mainly distributed on the greater omentum
and pelvic peritoneum. However, this was not the case. In current
study, we found that most of the patients (68.6%) had microscopic
peritoneal carcinomatosis located in the serosal surface of stomach,
and only 22.3% in greater omentum. Therefore, it was possible
that there were some other mechanisms which facilitated
peritoneal dissemination.
It was well-known that the prognosis of gastric cancer patients
with macroscopic peritoneal carcinomatosis or positive peritoneal
lavage cytology was dismal. It was reported that the prognosis of
patients with peritoneal carcinomatosis and ascites was very poor,
with a median survival of 3–6 months and no long-term survivors
[10,11]. Saito et al. [12] reported that the 5-year survival rate of
advance gastric cancer with intraperitoneal free cancer cells was
15.3%. Up to now, the prognosis and the clinicopathological
characteristics related to the prognosis of gastric cancer patients
with microscopic peritoneal carcinomatosis have not been
identified. In the current study, the 5-yr survival rate of patients
with microscopic peritoneal carcinomatosis was 24%, which was
significantly poorer than that of the gastric cancer without
Figure 1. There were significant differences in the survival
among three groups (patients with microscopic peritoneal
carcinomatosis: group 1; without microscopic peritoneal
carcinomatosis: group 2; with macroscopic peritoneal carcino-
matosis: group 3).
doi:10.1371/journal.pone.0037284.g001
Table 3. Multivariate analysis on factors in influencing
survival.
Variable x
2 P value Hazard ratio 95% CI
Sex 0.297 0.586 1.131 0.726–1.762
Age 0.325 0.569 1.130 0.742–1.723
Number of MPC* 2.068 0.150 1.351 0.897–2.037
Serosal invasion 0.173 0.678 0.762 0.211–2.750
The status of lymph
node
0.010 0.921 1.053 0.381–2.912
Pathological stage 11.474 0.001 1.780 1.275–2.484
Operation curability 27.844 0.000 0.212 0.119–0.378
*MPC microscopic peritoneal carcinomatosis.
doi:10.1371/journal.pone.0037284.t003
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gastric cancer with macroscopic peritoneal carcinomatosis. The
independent prognostic factors included: pathological stage and
operative curability. The 5-year survival rate was 28% in patients
with curative surgery, and 60% in patients with stage I/II. For the
19 patients presenting with stage I/II who underwent curative
surgery, the 5-year survival rate of these patients was 64%.
Therefore, good survival rate can be expected in I/II stage
patients with microscopic peritoneal carcinomatosis, who received
curative gastrectomy.
Although we firstly reported the prognosis of patients with
microscopic peritoneal carcinomatosis, there were some limita-
tions to this study. First, this study was limited by its retrospective
nature, and selection bias may have influenced survival data.
Second, intraoperative chemotherapy was not incorporated into
the analysis. Some studies have the efficacy of intraperitoneal
chemotherapy in gastric cancer patients with peritoneal dissem-
ination [13,14]. Third, the number of patients was small and a
larger number of patients would be required to confirm these
results. Fourth, although all the patients received resection of
peritoneum or biopsies of peritoneum, the part of resected
peritoneum only included greater omentum, lesser omentum,
and transverse mesocolon according to guideline of gastric cancer
therapy. Therefore, the frequency of gastric cancer with micro-
scopic peritoneal carcinomatosis might be higher than the
suggested.
In conclusion, the prognosis of gastric cancer patients with
microscopic peritoneal carcinomatosis was poorer than that of
patients without microscopic peritoneal carcinomatosis. Radical
surgery should be performed for early stage patients with
microscopic peritoneal carcinomatosis in order to improve survival
outcomes.
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